ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/n855mvkaoT https://t.co/1nCjL89Bfw

Study of 218 primary APS w/ Thrombocytopenia in 74 (34%) - such pts had signif. more visceral venous thromboses (13.5% vs. 3.5%), hemolytic anemia (27% vs. 12%), low C3/C4 (26% vs 11%), & higher pregnancy morbidity (HR 8.0, p = 0.0006) https://t.co/U9drB3gWq2 https://t.co/0EwItMO9N1

Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it? https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis This study identified genetic risk variants from genome-wide association analysis of OA patients to calculate PRSs associated with subsequent need for joint replacement surgery. https://t.co/65llG1nULF https://t.co/YQAJ9tIluF

New download available! Smart rules for patients—a patient handout. https://t.co/8yjCwb95c5 https://t.co/baFOavYO99

Diagnostic Delays in Spondyloarthritis Still Prolonged Previously quoted average delay in diagnosing axSpA may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between 5 and 6 years. https://t.co/6T9pck7nLa https://t.co/nwGBef2Gja

Our response to statins is influenced by our gut microbiome https://t.co/xKZdxO13va New @MedCellPress https://t.co/BxwhRhMAX9

Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/VvKZaeVumy https://t.co/1shpS0Ajn4

Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign? https://t.co/hl0HKggULj https://t.co/O1QMibJ4qA

NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/W6kjahdLEu https://t.co/QyTmlhb235

Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain An interesting read from @CreakyJoints. Check it out our synopsis. https://t.co/dHlUrWcyjB https://t.co/pL5Sn5eD7h